Clinical Trial Update: Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients [Phase 3]

View source ↗

Summary

A Phase 3 intergroup trial evaluating rituximab in high-risk pediatric patients with B-cell non-Hodgkin lymphoma or Burkitt leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Burkitt Leukemia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: B-cell Non Hodgkin Lymphoma, Mature B-cell Leukemia Burkitt-type | Phase 3 | Status: COMPLETED